Patent: 9,169,209
✉ Email this page to a colleague
Summary for Patent: 9,169,209
Title: | Compounds and compositions for the inhibition of NAMPT |
Abstract: | The present invention relates to compounds and composition for inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below. ##STR00001## |
Inventor(s): | Bair; Kenneth W. (Watertown, MA), Baumeister; Timm (Watertown, MA), Buckmelter; Alexandre J. (Watertown, MA), Clodfelter; Karl H. (Watertown, MA), Han; Bingsong (North Haven, CT), Lin; Jian (Acton, MA), Reynolds; Dominic J. (Stoneham, MA), Smith; Chase C. (Rutland, MA), Wang; Zhongguo (Watertown, MA), Zheng; Xiaozhang (Watertown, MA) |
Assignee: | FORMA TM, LLC (Watertown, MA) |
Application Number: | 14/115,623 |
Patent Claims: | see list of patent claims |
Details for Patent 9,169,209
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2031-05-04 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2031-05-04 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2031-05-04 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2031-05-04 | |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-05-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |